Wider Loss Expected at Hyseq

S&P sees more trouble ahead for the drug developer, driven by higher costs

Hyseq Inc. (HYSQ )

Year ending: Dec-01

Prior estimate: d1.48

New estimate: d1.65

Rationale: Higher costs

Zebra Technologies (ZBRA )

Year ending: Dec-01

Prior estimate: 3.30

New estimate: 2.83

Rationale: Economic slowdown

Before it's here, it's on the Bloomberg Terminal. LEARN MORE